|
EP1983000B1
(en)
|
2003-11-21 |
2015-09-02 |
UCB Biopharma SPRL |
Method for the treatment of multiple sclerosis by inhibiting IL-17 activity
|
|
PL1963368T6
(pl)
*
|
2005-12-13 |
2021-02-08 |
Eli Lilly And Company |
Przeciwciała anty-IL-17
|
|
JP2009534297A
(ja)
|
2006-03-10 |
2009-09-24 |
ザイモジェネティクス， インコーポレイテッド |
Ｉｌ−１７ａおよびｉｌ−１７ｆの両方に結合する抗体ならびにその使用方法
|
|
US7910703B2
(en)
|
2006-03-10 |
2011-03-22 |
Zymogenetics, Inc. |
Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
|
|
US7790163B2
(en)
|
2006-03-10 |
2010-09-07 |
Zymogenetics, Inc. |
Antibodies that bind both IL-17A and IL-17F and methods of using the same
|
|
TW200815469A
(en)
|
2006-06-23 |
2008-04-01 |
Astrazeneca Ab |
Compounds
|
|
GB0612928D0
(en)
|
2006-06-29 |
2006-08-09 |
Ucb Sa |
Biological products
|
|
NZ574804A
(en)
*
|
2006-08-11 |
2012-02-24 |
Schering Corp |
Antibodies to il-17a
|
|
GB0620729D0
(en)
|
2006-10-18 |
2006-11-29 |
Ucb Sa |
Biological products
|
|
NZ579594A
(en)
|
2007-03-12 |
2012-03-30 |
Esbatech Alcon Biomed Res Unit |
Sequence based engineering and optimization of single chain antibodies
|
|
CN101688200B
(zh)
|
2007-06-25 |
2012-08-08 |
艾斯巴技术,爱尔康生物医药研究装置有限责任公司 |
单链抗体的基于序列的改造和优化
|
|
NZ581468A
(en)
*
|
2007-06-25 |
2012-09-28 |
Esbatech Alcon Biomed Res Unit |
Methods of modifying antibodies, and modified antibodies with improved functional properties
|
|
WO2009026412A1
(en)
*
|
2007-08-21 |
2009-02-26 |
Children's Medical Center Corporation |
Treatment of airway hyperreactivity
|
|
WO2009082624A2
(en)
*
|
2007-12-10 |
2009-07-02 |
Zymogenetics, Inc. |
Antagonists of il-17a, il-17f, and il-23 and methods of using the same
|
|
GB0807413D0
(en)
|
2008-04-23 |
2008-05-28 |
Ucb Pharma Sa |
Biological products
|
|
BRPI0908312A2
(pt)
|
2008-05-05 |
2015-08-18 |
Novimmune Sa |
'' anticorpo monoclonal totalmente humano isolado, composição farmacêutica, método de alívio de um sintoma de uma indicação clínica e método de alívio de um sintoma de uma doença autoimune, distúrbio inflamatório ou distúrbio da proliferação celular''
|
|
CA2737636A1
(en)
*
|
2008-09-29 |
2010-04-01 |
Roche Glycart Ag |
Antibodies against human il17 and uses thereof
|
|
JP2012508563A
(ja)
*
|
2008-11-12 |
2012-04-12 |
シェーリング コーポレイション |
抗ＩＧＦ１Ｒ発現の増強のためのβＧｌ−ＩＧＧイントロン
|
|
US8211434B2
(en)
*
|
2008-11-26 |
2012-07-03 |
Allergan, Inc. |
KLK-13 antibody inhibitor for treating dry eye
|
|
US20110223169A1
(en)
*
|
2008-11-26 |
2011-09-15 |
Stern Michael E |
Il-17 antibody inhibitor for treating dry eye
|
|
NZ594514A
(en)
|
2009-03-05 |
2013-06-28 |
Abbott Lab |
Interleukin-17 BINDING PROTEINS
|
|
EP2427203B1
(en)
|
2009-05-05 |
2018-10-17 |
Novimmune S.A. |
Anti-il-17f antibodies and use thereof
|
|
WO2011053763A2
(en)
|
2009-10-30 |
2011-05-05 |
Centocor Ortho Biotech Inc. |
Il-17a antagonists
|
|
JO3417B1
(ar)
|
2010-01-08 |
2019-10-20 |
Regeneron Pharma |
الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
|
|
EP4450523A3
(en)
|
2010-04-02 |
2025-03-12 |
Amunix Pharmaceuticals, Inc. |
Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
|
|
WO2011141823A2
(en)
|
2010-05-14 |
2011-11-17 |
Orega Biotech |
Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
|
|
WO2012018767A2
(en)
*
|
2010-08-05 |
2012-02-09 |
Anaptysbio, Inc. |
Antibodies directed against il-17
|
|
TW201302793A
(zh)
*
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
MX356279B
(es)
*
|
2010-10-08 |
2018-05-22 |
Novartis Ag Star |
Métodos para el tratamiento de soriasis usando antagonistas de il-17.
|
|
US10208349B2
(en)
|
2011-01-07 |
2019-02-19 |
Ucb Biopharma Sprl |
Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
|
|
GB201100282D0
(en)
|
2011-01-07 |
2011-02-23 |
Ucb Pharma Sa |
Biological methods
|
|
PH12013501435B1
(en)
|
2011-01-14 |
2019-02-01 |
UCB Biopharma SRL |
Antibody molecules which bind il-17a and il-17f
|
|
US9943594B2
(en)
|
2011-10-11 |
2018-04-17 |
Sanofi Biotechnology |
Methods for the treatment of rheumatoid arthritis
|
|
TWI589299B
(zh)
|
2011-10-11 |
2017-07-01 |
再生元醫藥公司 |
用於治療類風濕性關節炎之組成物及其使用方法
|
|
RU2014125071A
(ru)
|
2011-11-21 |
2015-12-27 |
Новартис Аг |
Способы лечения псориатического артрита (psa) с использованием антагонистов il-17 и аллелей ответа psa или отсутствия ответа psa
|
|
EP2809660B1
(en)
|
2012-02-02 |
2016-01-20 |
Ensemble Therapeutics Corporation |
Macrocyclic compounds for modulating il-17
|
|
CA2866128C
(en)
|
2012-03-07 |
2017-02-28 |
Eli Lilly And Company |
Il-17 antibody formulation
|
|
AR090626A1
(es)
*
|
2012-04-20 |
2014-11-26 |
Lilly Co Eli |
Anticuerpos anti-baff-anti-il-17 biespecificos
|
|
CN104244979A
(zh)
|
2012-04-20 |
2014-12-24 |
诺华股份有限公司 |
使用il-17拮抗剂治疗强直性脊柱炎的方法
|
|
AR091116A1
(es)
|
2012-05-22 |
2015-01-14 |
Bristol Myers Squibb Co |
Anticuerpos biespecificos y sus metodos de uso
|
|
WO2014001368A1
(en)
|
2012-06-25 |
2014-01-03 |
Orega Biotech |
Il-17 antagonist antibodies
|
|
WO2014066726A2
(en)
|
2012-10-26 |
2014-05-01 |
Ensemble Therapeutics Corporation |
Compounds for modulating il-17
|
|
CN104936618A
(zh)
|
2012-11-29 |
2015-09-23 |
拜尔健康护理有限责任公司 |
针对活化蛋白c的人源化单克隆抗体及其用途
|
|
LT2953969T
(lt)
*
|
2013-02-08 |
2019-12-10 |
Novartis Ag |
Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui
|
|
TW201444867A
(zh)
*
|
2013-03-08 |
2014-12-01 |
Lilly Co Eli |
抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體
|
|
WO2014155278A2
(en)
|
2013-03-26 |
2014-10-02 |
Novartis Ag |
Methods of treating autoimmune diseases using il-17 antagonists
|
|
US9700485B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US20150004133A1
(en)
*
|
2013-06-07 |
2015-01-01 |
The Regents Of The University Of California |
Compositions And Methods For Treating Steatohepatitis, Liver Fibrosis, and Hepatocellular Carcinoma (HCC)
|
|
US9603882B2
(en)
|
2013-08-13 |
2017-03-28 |
Industrial Technology Research Institute |
Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells
|
|
US10434172B2
(en)
|
2013-08-15 |
2019-10-08 |
Novartis Ag |
Methods of treating generalized pustular psoriasis (GPP) using IL-17 antagonists
|
|
US9862765B2
(en)
|
2013-11-18 |
2018-01-09 |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
IL-17A binding agent and uses thereof
|
|
AU2014370875B2
(en)
*
|
2013-12-27 |
2017-11-23 |
Osaka University |
Vaccine targeting IL-17A
|
|
AU2014374055B2
(en)
|
2013-12-30 |
2018-11-08 |
Epimab Biotherapeutics Inc. |
Fabs-in-tandem immunoglobulin and uses thereof
|
|
JP2017507939A
(ja)
|
2014-02-21 |
2017-03-23 |
ジェネンテック， インコーポレイテッド |
抗ｉｌ−１３／ｉｌ−１７二重特異性抗体及びその使用
|
|
RU2577228C2
(ru)
*
|
2014-03-14 |
2016-03-10 |
Закрытое Акционерное Общество "Биокад" |
Анти-il-17-антитела, способ их получения и способ применения
|
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
|
FI3191120T3
(fi)
|
2014-09-10 |
2024-07-10 |
Novartis Ag |
Il-17-antagonistien käyttö rakennevaurion etenemisen estämiseksi nivelpsoriaasipotilailla
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
SG11201702401RA
(en)
|
2014-10-14 |
2017-04-27 |
Novartis Ag |
Antibody molecules to pd-l1 and uses thereof
|
|
AR103173A1
(es)
|
2014-12-22 |
2017-04-19 |
Novarits Ag |
Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
|
|
KR20240110106A
(ko)
|
2015-01-12 |
2024-07-12 |
애피바디 에이비 |
Il-17a-결합 폴리펩티드
|
|
EP3250927B1
(en)
|
2015-01-28 |
2020-02-19 |
H. Hoffnabb-La Roche Ag |
Gene expression markers and treatment of multiple sclerosis
|
|
CN106336459B
(zh)
*
|
2015-07-13 |
2020-12-08 |
三生国健药业（上海）股份有限公司 |
抗人白细胞介素-17a单克隆抗体、其制备方法和应用
|
|
KR20180017145A
(ko)
|
2015-07-16 |
2018-02-20 |
일라이 릴리 앤드 캄파니 |
소양증의 치료
|
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
US20180340025A1
(en)
|
2015-07-29 |
2018-11-29 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
|
US11077187B2
(en)
|
2015-11-17 |
2021-08-03 |
Oklahoma Medical Research Foundation |
Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
|
|
CN108495651A
(zh)
|
2015-12-17 |
2018-09-04 |
诺华股份有限公司 |
抗pd-1的抗体分子及其用途
|
|
JP7014724B2
(ja)
|
2016-02-06 |
2022-02-01 |
エピムアブ バイオセラピューティクス インコーポレイテッド |
タンデム型Ｆａｂ免疫グロブリンおよびその使用
|
|
CN107488227A
(zh)
*
|
2016-06-12 |
2017-12-19 |
三生国健药业（上海）股份有限公司 |
抗人白细胞介素‑17a单克隆抗体、其制备方法和应用
|
|
WO2017221174A1
(en)
|
2016-06-22 |
2017-12-28 |
Novartis Ag |
Methods of treating vitiligo using interleukin-17 (il-17) antibodies
|
|
EP3487881B1
(en)
|
2016-07-19 |
2024-08-21 |
Novartis AG |
Methods of treating new-onset plaque type psoriasis using il-17 antagonists
|
|
TN2019000082A1
(en)
|
2016-09-14 |
2020-07-15 |
Beijing hanmi pharm co ltd |
Antibody specifically binding to il-17a and functional fragment thereof
|
|
JP2019505516A
(ja)
|
2016-11-28 |
2019-02-28 |
ノバルティス アーゲー |
インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
|
|
CN116715775A
(zh)
|
2017-02-10 |
2023-09-08 |
豪夫迈·罗氏有限公司 |
抗类胰蛋白酶抗体、其组合物及其用途
|
|
WO2018158741A1
(en)
|
2017-03-03 |
2018-09-07 |
Novartis Ag |
Psoriasis disease modification following long-term treatment with an il-17 antagonist
|
|
KR102321861B1
(ko)
*
|
2017-03-10 |
2021-11-05 |
쑤저우 카노바 바이오파마슈티컬 컴퍼니 리미티드 |
Il-17a 및 il-17f 모두에 대한 단일클론 항체 및 이의 용도
|
|
US10941178B2
(en)
*
|
2017-03-17 |
2021-03-09 |
Gilead Sciences, Inc. |
Method of purifying an antibody
|
|
US10676522B2
(en)
|
2017-05-05 |
2020-06-09 |
Novartis Ag |
Methods of selectively treating asthma using IL-17 antagonists
|
|
WO2018236728A1
(en)
|
2017-06-18 |
2018-12-27 |
Kindred Biosciences, Inc. |
ANTIBODIES AND ANTAGONISTS OF IL17A FOR VETERINARY USE
|
|
WO2019027828A1
(en)
|
2017-08-04 |
2019-02-07 |
Eli Lilly And Company |
DOSAGE SCHEME OF ANTI-IL-17 ANTIBODIES
|
|
EP3672988A1
(en)
|
2017-08-23 |
2020-07-01 |
Eli Lilly and Company |
Treatment of genital psoriasis
|
|
AU2018361975A1
(en)
|
2017-11-02 |
2020-05-07 |
Novartis Ag |
Method of treating tendinopathy using interleukin-17 (IL-17) antagonists
|
|
KR102048475B1
(ko)
*
|
2017-11-10 |
2019-11-26 |
주식회사 와이바이오로직스 |
IL-17A (Interleukin-17A)에 특이적으로 결합하는 항체 및 이의 용도
|
|
EP3712170A4
(en)
*
|
2017-11-10 |
2022-03-02 |
Jiangsu Hengrui Medicine Co., Ltd. |
CD96 ANTIBODY, ANTIGEN BINDING FRAGMENT AND PHARMACEUTICAL USE THEREOF
|
|
US20200277369A1
(en)
|
2017-11-20 |
2020-09-03 |
Novartis Ag |
Method of treating hidradentitis suppurativa with il-17 antagonists
|
|
MX2020005651A
(es)
|
2017-11-30 |
2020-10-28 |
Novartis Ag |
Receptor de antigeno quimerico dirigido a bcma y usos del mismo.
|
|
US11619832B2
(en)
|
2018-03-08 |
2023-04-04 |
Coopervision International Limited |
Identification of contact lens wearers predisposed to contact lens discomfort
|
|
CN112074541A
(zh)
|
2018-05-03 |
2020-12-11 |
上海岸迈生物科技有限公司 |
Pd-1和lag-3的高亲和力抗体以及由其制备的双特异性结合蛋白
|
|
JP6930778B2
(ja)
*
|
2018-05-17 |
2021-09-01 |
江蘇▲筌▼信生物医薬有限公司Ｑｙｕｎｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏ．， Ｌｔｄ． |
抗ヒトインターロイキン１７ａモノクローナル抗体およびその使用
|
|
CN110551215A
(zh)
|
2018-05-30 |
2019-12-10 |
中山康方生物医药有限公司 |
抗白细胞介素-17a抗体、其药物组合物及其用途
|
|
PE20210320A1
(es)
|
2018-06-01 |
2021-02-16 |
Novartis Ag |
Moleculas de union contra bcma y usos de las mismas
|
|
GB201810327D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicycletx Ltd |
Peptide ligands for binding to IL-17
|
|
KR20260109977A
(ko)
|
2018-08-29 |
2026-07-13 |
리제너론 파아마슈티컬스, 인크. |
류마티스성 관절염을 갖는 대상체를 치료하기 위한 방법 및 조성물
|
|
EP3856772A1
(en)
|
2018-09-25 |
2021-08-04 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
|
|
CN111018974B
(zh)
*
|
2018-10-10 |
2022-04-01 |
东莞市朋志生物科技有限公司 |
一种抗人心肌肌钙蛋白i的重组抗体
|
|
GB201820316D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for IL-17
|
|
CN109369806B
(zh)
*
|
2019-01-14 |
2019-04-19 |
迈威(上海)生物科技有限公司 |
苏金单抗制品中半胱氨酸化变异体的去除方法
|
|
JP7542543B2
(ja)
|
2019-01-31 |
2024-08-30 |
サノフィ・バイオテクノロジー |
若年性特発性関節炎を治療するための抗ｉｌ－６受容体抗体
|
|
EP3689907A1
(en)
|
2019-01-31 |
2020-08-05 |
Numab Therapeutics AG |
Antibodies targeting il-17a and methods of use thereof
|
|
JP7525499B2
(ja)
|
2019-01-31 |
2024-07-30 |
ヌマブ セラピューティクス アクチェンゲゼルシャフト |
ＴＮＦα及びＩＬ－１７Ａに対する特異性を有する多重特異性抗体、ＩＬ－１７Ａを標的とする抗体、及びそれらの使用方法
|
|
PE20212185A1
(es)
|
2019-02-18 |
2021-11-11 |
Lilly Co Eli |
Formulacion de anticuerpos terapeuticos
|
|
JP2022545312A
(ja)
|
2019-04-24 |
2022-10-27 |
サノフィ・バイオテクノロジー |
関節リウマチの診断及び処置の方法
|
|
KR102400401B1
(ko)
*
|
2019-05-22 |
2022-05-24 |
(주)셀인바이오 |
항염증 펩타이드 및 항염증 조성물
|
|
CA3142710A1
(en)
|
2019-06-04 |
2020-12-10 |
Sanofi Biotechnology |
Compositions and methods for treating pain in subjects with rheumatoid arthritis
|
|
ES3059248T3
(en)
|
2019-07-26 |
2026-03-19 |
Sinocelltech Ltd |
Humanized anti-il17a antibody and use thereof
|
|
WO2021018191A1
(zh)
|
2019-07-30 |
2021-02-04 |
江苏恒瑞医药股份有限公司 |
Il-17拮抗剂治疗自身免疫疾病的方法
|
|
EP4031570A1
(en)
|
2019-09-20 |
2022-07-27 |
Novartis AG |
Methods of treating autoimmune diseases using interleukin-17 (il-17) antagonists
|
|
EP4045641A1
(en)
|
2019-10-15 |
2022-08-24 |
Eli Lilly and Company |
Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
|
|
WO2021099924A1
(en)
|
2019-11-19 |
2021-05-27 |
Novartis Ag |
Methods of treating lupus nephritis using interleukin-17 (il-17) antagonists
|
|
JP2023504679A
(ja)
|
2019-12-06 |
2023-02-06 |
ノバルティス アーゲー |
インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して扁平苔癬を治療する方法
|
|
GB201918558D0
(en)
|
2019-12-16 |
2020-01-29 |
Bicycle Tx Ltd |
Bicyclic peptide ligands specific for IL-17
|
|
GB201918557D0
(en)
|
2019-12-16 |
2020-01-29 |
Bicycle Tx Ltd |
Bicyclic peptide ligands specific for IL-17
|
|
EP4077349A1
(en)
|
2019-12-16 |
2022-10-26 |
BicycleTX Limited |
Bicyclic peptide ligands specific for il-17
|
|
GB201918559D0
(en)
|
2019-12-16 |
2020-01-29 |
Bicycle Tx Ltd |
Bicyclic peptide ligands specific for IL-17
|
|
GB201919062D0
(en)
*
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Antibody
|
|
MX2022014925A
(es)
|
2020-05-27 |
2023-01-04 |
Sanofi Sa |
Moduladores de il-17a.
|
|
EP4157828A1
(en)
|
2020-05-27 |
2023-04-05 |
Sanofi |
Il-17a modulators
|
|
US20230235041A1
(en)
|
2020-06-23 |
2023-07-27 |
Novartis Ag |
Methods of treating thyroid eye disease and graves' orbitopahy using interleukin-17 (il-17) antagonists
|
|
AU2021373366A1
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
CN115746132B
(zh)
*
|
2021-09-03 |
2023-09-08 |
三优生物医药(上海)有限公司 |
抗il-17a抗体及其用途
|
|
IT202100023816A1
(it)
*
|
2021-09-16 |
2023-03-16 |
Takis S R L |
Anticorpo contro SARS-CoV-2 e suoi usi in campo medico.
|
|
CN113896793B
(zh)
*
|
2021-09-30 |
2023-05-26 |
港科鹏禾生物(苏州)有限公司 |
一种抗人il-17rc的单克隆抗体及其应用
|
|
JP2025516772A
(ja)
|
2022-05-16 |
2025-05-30 |
ノバルティス アーゲー |
インターロイキン－１７（ｉｌ－１７）アンタゴニストを用いて巨細胞性動脈炎を治療する方法
|
|
AU2023270497A1
(en)
|
2022-05-18 |
2024-12-05 |
Novartis Ag |
Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists
|
|
JP2026500183A
(ja)
|
2022-12-09 |
2026-01-06 |
サノフイ |
治療用化合物
|
|
WO2025083549A1
(en)
|
2023-10-16 |
2025-04-24 |
Sun Pharma Advanced Research Company Limited |
Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders
|
|
WO2025104230A1
(en)
|
2023-11-17 |
2025-05-22 |
Sanofi |
Benzoxazoles as modulators of il-17a
|
|
WO2025248073A1
(en)
|
2024-05-30 |
2025-12-04 |
Sanofi |
Therapeutic compounds
|
|
TW202617180A
(zh)
*
|
2024-06-20 |
2026-05-01 |
南韓商賽特瑞恩股份有限公司 |
穩定的藥學製劑
|
|
CN120249218B
(zh)
*
|
2024-10-15 |
2026-03-20 |
武汉纺织大学 |
一种分泌抗微纳塑料广谱性单克隆抗体的杂交瘤细胞株及其应用
|